3m-052-af
Small moleculeexperimental
Clinical trial activity
7 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 18, 2019 (NCT04177355)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Toll-like receptor 8AGONIST
TLR8 agonist
- Toll-like receptor 7AGONIST
TLR7 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06680479 | Phase 1 | Feb 15, 2025 | Access to Advanced Health Institute (AAHI), Duke University, National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh |
| NCT06613789 | Phase 1 | Feb 3, 2025 | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of Washington |
| NCT06267872 | Phase 1 | Oct 7, 2024 | Access to Advanced Health Institute (AAHI), Department of Health and Human Services, Duke University, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT06334393 | Phase 1 | Mar 25, 2024 | Valneva |
| NCT05903339 | Phase 1 | Aug 29, 2023 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05781542 | Phase 1 | Apr 10, 2023 | Access to Advanced Health Institute (AAHI), Department of Health and Human Services, HIV Vaccine Trials Network, Inovio Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID), The Wistar Institute |
| NCT04177355 | Phase 1 | Dec 18, 2019 | Dynavax Technologies Corporation, Emory University, HIV Vaccine Trials Network, Infectious Disease Research Institute, International AIDS Vaccine Initiative, National Institute of Allergy and Infectious Diseases (NIAID), University of Washington |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 6 | 5 | 1 | 2019 |
| Access to Advanced Health Institute (AAHI) | Academic/Hospital | 3 | 0 | 1 | 2023 |
| HIV Vaccine Trials Network | Academic/Hospital | 3 | 1 | 1 | 2019 |
| Department of Health and Human Services | Government | 2 | 0 | 1 | 2023 |
| Duke University | Academic/Hospital | 2 | 0 | 1 | 2024 |
| University of Washington | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Dynavax Technologies Corporation | For profit | 1 | 0 | 1 | 2019 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Infectious Disease Research Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Inovio Pharmaceuticals | For profit | 1 | 0 | 1 | 2023 |
| International AIDS Vaccine Initiative | Academic/Hospital | 1 | 0 | 1 | 2019 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2024 |
| The Wistar Institute | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Valneva | For profit | 1 | 1 | 1 | 2024 |
15 organizations
Page 1 / 1